Recent TRAIL Engineering Strategies for Precise Strike Therapy Against Tumor

Biomaterials Research, Journal Year: 2025, Volume and Issue: 29

Published: Jan. 1, 2025

Effective drug delivery relies on the selection of suitable carriers, which is crucial for protein-based therapeutics such as tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). One key advantages TRAIL its ability to selectively induce apoptosis in cancer cells excluding healthy tissues by binding death receptors DR4 and DR5, are highly expressed various cells. Despite this promise, clinical application has been limited short half-life, stability, inefficient sites. To overcome currently available engineering approaches, a series sophisticated strategies required: (a) design biomaterial-mediated carriers enhanced targeting efficacy, particularly via optimizing selected materials, composition, formulation, surface modulation. Moreover, (b) development genetically modified cellular products augmented secretion toward microenvironments (c) cell techniques immobilization onto infusible populations also discussed present review. Among these living cell-based offer distinct advantage systemically administered TRAIL-functionalized capturing circulating bloodstream, thereby preventing secondary formation. This review provides insight into novel platforms, discusses considerations translation, suggests future directions complementary advance field TRAIL-based therapeutics.

Language: Английский

Amphiphilic Lipid-Peptide Engineered Placenta-Derived Mesenchymal Stem Cells for Liver Fibrosis Treatment

Asian Journal of Pharmaceutical Sciences, Journal Year: 2025, Volume and Issue: unknown, P. 101061 - 101061

Published: April 1, 2025

Language: Английский